SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Trial Profile

SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Sirolimus
  • Indications Sickle cell anaemia; Transplant rejection
  • Focus Therapeutic Use
  • Acronyms SCD-Haplo
  • Most Recent Events

    • 24 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top